POWELL MICHAEL

CIK 000120279332 companiesSAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001202793

Recent Transactions

50 trades

Award
Bicara Therapeutics Inc.$BCAX
Stock Option (Right to Buy)
2025-06-09+23,746→ 23,746 total
Award
Galera Therapeutics, Inc.$GRTX
Stock Option (Right to Buy)
2023-06-14+64,000→ 64,000 total
Award
Galera Therapeutics, Inc.$GRTX
Stock Option (Right to Buy)
2022-06-15+20,000→ 20,000 total
Disposition to Issuer
Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2022-05-31−10,030→ 0 total
Disposition to Issuer
Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2022-05-31−30,000→ 0 total
Disposition to Issuer
Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2022-05-31−30,000→ 0 total
Award
Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2021-08-09+30,000→ 30,000 total
Award
Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2021-06-16+10,030→ 10,030 total
Award
Galera Therapeutics, Inc.$GRTX
Stock Option (Right to Buy)
2021-06-16+13,179→ 13,179 total
Conversion
Vera Therapeutics, Inc.$VERA
Series C Preferred Stock
2021-05-18−2,187,504→ 0 total
Purchase
Vera Therapeutics, Inc.$VERA
Class A Common Stock
2021-05-18$11.00/sh+727,272→ 2,914,776 total
Conversion
Vera Therapeutics, Inc.$VERA
Class A Common Stock
2021-05-18+2,187,504→ 2,187,504 total
Purchase
Bolt Biotherapeutics, Inc.$BOLT
Common Stock
2021-02-09$20.00/sh+450,000→ 2,754,437 total
Conversion
Bolt Biotherapeutics, Inc.$BOLT
Series C-2 Preferred Stock
2021-02-09−1,200,228→ 0 total
Conversion
Bolt Biotherapeutics, Inc.$BOLT
Common Stock
2021-02-09+1,104,209→ 1,104,209 total
Conversion
Bolt Biotherapeutics, Inc.$BOLT
Series C-1 Preferred Stock
2021-02-09−1,104,209→ 0 total
Conversion
Bolt Biotherapeutics, Inc.$BOLT
Common Stock
2021-02-09+1,200,228→ 2,304,437 total
Award
Checkmate Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2020-11-10+30,000→ 30,000 total
Conversion
Checkmate Pharmaceuticals, Inc.
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total
Conversion
Checkmate Pharmaceuticals, Inc.
Common Stock
2020-08-11+3,473,374→ 3,473,374 total
Conversion
Checkmate Pharmaceuticals, Inc.
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total
Conversion
Checkmate Pharmaceuticals, Inc.
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total
Purchase
Checkmate Pharmaceuticals, Inc.
Common Stock
2020-08-11$15.00/sh+133,333→ 3,606,707 total
Conversion
Inozyme Pharma, Inc.
Common Stock
2020-07-28+1,590,808→ 1,590,808 total
Conversion
Inozyme Pharma, Inc.
Series A-2 Convertible Preferred Stock
2020-07-28−11,888,112→ 0 total
Purchase
Inozyme Pharma, Inc.
Common Stock
2020-07-28$16.00/sh+437,500→ 2,028,308 total
Conversion
Akouos, Inc.
Common Stock
2020-06-30+856,262→ 856,262 total
Conversion
Akouos, Inc.
Series A Preferred Stock
2020-06-30−18,044,028→ 0 total
Conversion
Akouos, Inc.
Series B Preferred Stock
2020-06-30−12,643,557→ 0 total
Purchase
Akouos, Inc.
Common Stock
2020-06-30$17.00/sh+58,823→ 1,515,073 total
Conversion
Akouos, Inc.
Common Stock
2020-06-30+599,988→ 1,456,250 total
Award
Galera Therapeutics, Inc.$GRTX
Stock Option (Right to Buy)
2020-06-09+13,179→ 13,179 total
Sale
Iterum Therapeutics plc$ITRM
Ordinary Shares
2020-06-02$1.61/sh−400,000→ 1,226,514 total
Sale
Iterum Therapeutics plc$ITRM
Ordinary Shares
2020-06-01$1.69/sh−100,000→ 1,626,514 total
Award
Iterum Therapeutics plc$ITRM
6.500% Exchangeable Senior Subordinated Note due 2025
2020-01-21$1750000.00/sh
Purchase
NextCure, Inc.$NXTC
Common Stock
2019-11-15$36.75/sh+150,000→ 2,671,856 total
Conversion
Galera Therapeutics, Inc.$GRTX
Series B-2 Preferred Stock
2019-11-12−9,090,909→ 0 total
Conversion
Galera Therapeutics, Inc.$GRTX
Common Stock
2019-11-12+2,333,712→ 2,333,712 total
Purchase
Galera Therapeutics, Inc.$GRTX
Common Stock
2019-11-12$12.00/sh+750,000→ 3,083,712 total
Conversion
Galera Therapeutics, Inc.$GRTX
Series C Preferred Stock
2019-11-12−2,709,659→ 0 total
Award
Galera Therapeutics, Inc.$GRTX
Stock Option
2019-11-06+19,776→ 19,776 total
Award
SYNLOGIC, INC.$SYBX
Stock Option (right to buy)
2019-06-05+10,000→ 10,000 total
Conversion
NextCure, Inc.$NXTC
Common Stock
2019-05-13+908,785→ 1,652,143 total
Conversion
NextCure, Inc.$NXTC
Common Stock
2019-05-13+278,759→ 278,759 total
Conversion
NextCure, Inc.$NXTC
Common Stock
2019-05-13+469,713→ 2,121,856 total
Conversion
NextCure, Inc.$NXTC
Common Stock
2019-05-13+464,599→ 743,358 total
Purchase
NextCure, Inc.$NXTC
Common Stock
2019-05-13$15.00/sh+400,000→ 2,521,856 total
Conversion
NextCure, Inc.$NXTC
Series A-1 Preferred Stock
2019-05-13−2,239,500→ 0 total
Conversion
NextCure, Inc.$NXTC
Series A-2 Preferred Stock
2019-05-13−3,732,500→ 0 total
Conversion
NextCure, Inc.$NXTC
Series A-3 Preferred Stock
2019-05-13−7,301,000→ 0 total

Companies

Recent Filings

Address

C/O SOFINNOVA VENTURES, INC. 140 GEARY STREET 10TH FLOOR

SAN FRANCISCO, CA, 94108

View on SEC.gov